|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.29 USD | +2.46% |
|
-9.31% | +41.07% |
| 07-16 | Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating | MT |
| 07-14 | Biogen's Alzheimer's drug lowers toxic protein, but results were mixed | RE |
| Market Cap | 3.7B 3.23B 2.98B 2.75B 5.18B 356B 5.29B 35.63B 14.01B 174B 13.88B 13.58B 600B | P/E 2026 * |
-9.5x | P/E 2027 * | -9.67x |
|---|---|---|---|---|---|
| Enterprise Value | 3.02B 2.64B 2.44B 2.25B 4.23B 291B 4.33B 29.13B 11.46B 143B 11.35B 11.1B 491B | EV / Sales 2026 * |
76x | EV / Sales 2027 * | 27.4x |
| Free-Float |
90.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Denali Therapeutics Inc.
| 1 day | +2.46% | ||
| 1 week | -9.31% | ||
| Current month | -9.45% | ||
| 1 month | -0.09% | ||
| 3 months | +13.22% | ||
| 6 months | +29.46% | ||
| Current year | +41.07% |
| 1 week | 22.01 |  | 26.6 |
| 1 month | 22.01 | | 27.3 |
| Current year | 15.34 | | 27.3 |
| 1 year | 12.58 | | 27.3 |
| 3 years | 10.57 | | 33.33 |
| 5 years | 10.57 | | 66.79 |
| 10 years | 10.57 | | 93.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
DFI | Director of Finance/CFO | 52 | 01/05/2022 |
Ryan Watts
CEO | Chief Executive Officer | 50 | 01/08/2015 |
Peter Chin
CTO | Chief Tech/Sci/R&D Officer | 58 | 06/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Watts
BRD | Director/Board Member | 50 | 01/03/2015 |
Jay Flatley
BRD | Director/Board Member | 73 | 01/04/2015 |
David Schenkein
BRD | Director/Board Member | 68 | 01/04/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/3/26 A | Free | Director | 25,634 | 0.0162% | ||
| 6/3/26 A | Free | Director | 25,634 | 0.0162% | ||
| 6/3/26 A | Free | Director | 25,634 | 0.0162% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.46% | -9.31% | +66.36% | -21.58% | 3.7B | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.25% | -3.29% | +43.12% | +163.48% | 23.72B | |
| Weighted average by Cap. | -2.72% | -2.46% | +39.96% | +140.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 39.76M 34.75M 32.06M 29.55M 55.7M 3.83B 56.94M 383M 151M 1.88B 149M 146M 6.46B | 111M 96.84M 89.36M 82.37M 155M 10.67B 159M 1.07B 420M 5.23B 416M 407M 17.99B |
| Net income | -484M -423M -390M -360M -678M -46.62B -693M -4.67B -1.84B -22.83B -1.82B -1.78B -78.61B | -466M -408M -376M -347M -653M -44.91B -668M -4.5B -1.77B -22B -1.75B -1.71B -75.72B |
| Net Debt | -674M -589M -544M -501M -945M -64.95B -966M -6.5B -2.56B -31.81B -2.53B -2.48B -110B | -663M -579M -535M -493M -929M -63.85B -950M -6.39B -2.51B -31.27B -2.49B -2.44B -108B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | $23.29 | +2.46% | 1,611,464 |
| 16/07/26 | $22.73 | -1.26% | 2,441,932 |
| 15/07/26 | $23.02 | +1.63% | 1,889,604 |
| 14/07/26 | $22.65 | -14.46% | 5,778,165 |
| 13/07/26 | $26.48 | +3.12% | 1,894,568 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DNLI Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
